Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO) Files An 8-K Regulation FD DisclosureItem 7.01.
The Company has received some shareholder inquiries about whether the Company will be presenting at the SMi conference in London on September 27-28, 2017. While anticipating the disclosure of interim blinded data from the Company’s Phase 3 trial of DCVax®-L for Glioblastoma, the Company will not be presenting at this year’s SMi conference. SMi will be posting this same information on their website and in the conference program.
About Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO)
Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing immunotherapy products to treat cancer. One of the product lines (DCVax-L) is designed to cover all solid tumor cancers in which the tumors can be surgically removed. Another product line (DCVax-Direct) is designed for all solid tumor cancers. The Company’s lead product, DCVax-L, is in an ongoing Phase III trial for diagnosed Glioblastome multiforme (GBM), with over 60 trial sites. Its second product, DCVax-Direct, is being studied in a 60-patient Phase I/II trial for all types of inoperable solid tumors. The 40-patient Phase I stage of the trial has been completed. The Company is working on preparations for Phase II trials of DCVax-Direct. The Company’s platform technology, DCVax, uses activated dendritic cells to mobilize a patient’s own immune system, including T cells, B cells and antibodies and natural killer cells, among others to attack cancer cells to attack their cancer.